Revmatologicky Ustav — Clinical Trial Site

63 Registered trials

19 Currently recruiting

Organisation

Revmatologicky Ustav

Location

Prague 2, Czechia

Identifier

ORG-100042400

Address

Na Slupi 450/4, Nove Mesto, 128 00, Czechia

Departments

#2203: Revmatologie
#2751: Revmatologicky Ustav
#3051
#3205:Revmatologie
#40016
#40066
1601: Department of Experimental Rheumatology
1701: Rheumatology
2001: Revmatologie
2002:Rheumatology
2043: Revmatologie
2105: Revmatologie
3051; Revmatologie
7304
Ambulantní část klinického oddělení Oddělení experimentální revmatologie
CZ10014
Department of Rheumatology
Dpt of experimental rheumatology
Institute of Rheumatology, Department of Rheumatology
N/A
NA
Not applicable
Oddeleni experimentalni revmatologie
Oddeleni klinickych hodnoceni
Revmatologické oddělení
Revmatologicky ustav
Rheumatology
Scientific Research Center
Scientific Research Centre
Vědeckovýzkumné centrum

Clinical trials at this site (63)

Search interface

A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a… Ended

2022-501895-25-00 Polymyalgia Rheumatica 5 2023-09-13
A Phase 2 proof of concept study to evaluate the efficacy and safety of daxdilimab in participants with dermatomyositis or anti-synthetase i… Ended

2022-502810-10-00 Dermatomyositis (DM) or anti-synthetase inflammatory my 4 2023-09-12
A study evaluating the effects of GLPG3667 given as oral treatment for up to 24 weeks in adults with dermatomyositis Ended

2022-501097-19-00 dermatomyositis 4 2023-08-09
Study of M5049 in DM and PM Participants (NEPTUNIA) Ended

2022-501351-82-00 Dermatomyositis, Polymyositis 4 2023-05-23
A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended

2022-500332-11-00 systemic sclerosis 4 2022-11-25
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of Baricit… Ended

2024-518556-22-00 polymyalgia rheumatica 5 2022-05-10
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia… Ended

2024-510744-31-00 Giant cell arteritis (GCA) 5 2021-10-06
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Su… Ended

2024-512142-42-00 Psoriatic Arthritis 5 2021-10-05
Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One… Ended

2023-504715-33-00 Psoriatic Arthritis 5 2021-09-27
Study of efficacy, safety, and tolerability of LNA043 in patients with symptomatic knee osteoarthritis Ended

2023-509937-37-00 Osteoarthritis 4 2021-07-21
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien… Ended

2023-507415-35-00 Psoriatic Arthritis 5 2021-01-15
An extension study to learn if Bimekizumab works and is safe over a long period in adults with Active Axial Spondyloarthritis. Ended

2023-506527-28-00 Axial Spondyloarthritis 5 2020-06-29
Evaluation of upadacitinib in adult subjects with axial spondyloarthritis Ended

2022-501018-78-00 Axial Spondyloarthritis 5 2020-03-23
Phase 3b/4 Study in Rheumatoid Arthritis Ended

2023-508022-10-00 Rheumatoid Arthritis 6 2019-07-25
A Phase 2a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Burfiralimab (hzVSF-v13)… Ended

2023-507944-35-00 rheumatoid arthritis 4